Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1920 NABICAT
jRCTs031200388Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin and tegafur in biliary cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
gemcitabinecisplatintegafur
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs031200388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200388.